Barrett's esophagus pathophysiology: Difference between revisions
Jump to navigation
Jump to search
Amresh Kumar (talk | contribs) |
Amresh Kumar (talk | contribs) |
||
| Line 11: | Line 11: | ||
* There are [[many]] [[histological]] [[mimics]] of [[Barrett's esophagus]] (i.e. [[goblet cells]] occurring in the [[transitional epithelium]] of [[normal]] [[esophageal]] [[submucosal]] gland ducts, "pseudogoblet cells" in which abundant foveolar (gastric) type [[mucin]] simulates the [[acid]] [[mucin]] true [[goblet cells]]). Assessment of relationship to [[submucosal glands]] and [[transitional-type epithelium]] with [[examination]] of multiple levels through the [[tissue]] may allow the [[pathologist]] to reliably distinguish between [[goblet cells]] of [[submucosal gland ducts]] and true [[Barrett's esophagus]] (specialized columnar [[metaplasia]]). Use of the histochemical [[stain]] Alcian [[blue]] (with [[pH]]=2.5) is also frequently used to distinguish true intestinal-type [[mucin]] from their [[histological]] [[mimics]]. Recently, [[immunohistochemical]] [[analysis]] with [[antibodies]] to CDX-2 (specific for mid and [[hind-gut]] [[intestinal]] derivation) has also been utilized to identify true intestinal-type metaplastic cells. | * There are [[many]] [[histological]] [[mimics]] of [[Barrett's esophagus]] (i.e. [[goblet cells]] occurring in the [[transitional epithelium]] of [[normal]] [[esophageal]] [[submucosal]] gland ducts, "pseudogoblet cells" in which abundant foveolar (gastric) type [[mucin]] simulates the [[acid]] [[mucin]] true [[goblet cells]]). Assessment of relationship to [[submucosal glands]] and [[transitional-type epithelium]] with [[examination]] of multiple levels through the [[tissue]] may allow the [[pathologist]] to reliably distinguish between [[goblet cells]] of [[submucosal gland ducts]] and true [[Barrett's esophagus]] (specialized columnar [[metaplasia]]). Use of the histochemical [[stain]] Alcian [[blue]] (with [[pH]]=2.5) is also frequently used to distinguish true intestinal-type [[mucin]] from their [[histological]] [[mimics]]. Recently, [[immunohistochemical]] [[analysis]] with [[antibodies]] to CDX-2 (specific for mid and [[hind-gut]] [[intestinal]] derivation) has also been utilized to identify true intestinal-type metaplastic cells. | ||
* | * In the [[United States]], it is estimated that 8 - 12% of [[patients]] who are [[diagnosed]] with [[Barrett's esophagus]] have been misdiagnosed. This significant [[diagnostic]] [[error]] may [[result]] in higher [[rates]] of [[medical]] and [[life]] [[insurance]] [[rates]] for those [[misdiagnosed]]; as well as enrollment of [[patients]] in unnecessary surveillance programs (i.e. annual [[endoscopic]] evaluation and [[biopsy]] to monitor for the development of [[Barrett's esophagus]]). [[Second]] (consulting) opinions on [[pathologic]] [[materials]] [[are]] [[easily]] [[available]] [[as]] [[slides]] [[and]] [[tissue blocks]] [[are]] [[retained]] [[for] 10 and 20 [[years]], [[respectively]]. [[To]] [[request]] [[a]] [[consultation]] [[opinion]], [[patients]] [[may]] [[contact]] [[their]] [[gastroenterologist]] [[for]] [[referral]] [[to]] [[a]] [[GI]] [[pathology]] [[specialty]] [[center]]. | ||
* [[After]] [[the]] [[initial]] [[diagnosis]] [[of]] [[Barrett's esophagus]] [[is]] [[rendered]], [[affected]] [[persons]] [[undergo]] [[annual]] [[surveillance]] [[to]] [[detect]] [[changes]] [[that]] [[indicate]] [[higher]] [[risk]] [[to]] [[progression]] [[to]] [[cancer]]: [[development]] [[of]] [[dysplasia]]. [[There]] [[is]] [[considerable]] [[variability]] [[in]] [[assessment]] [[for]] [[dysplasia]] [[among]] [[pathologists]]. [[Recently]], [[gastroenterology]] and [[GI]] [[pathology]] [[societies]] [[have]] [[recommended]] [[that]] [[any]] [[diagnosis]] [[of]] [[high]] [[grade]] [[dysplasia]] [[in]] [[Barrett's]] [[be]] [[confirmed]] [[by]] [[at]] [[least]] [[two]] [[fellowship]] [[trained]] [[GI]] [[pathologists]] [[prior]] [[to]] [[definitive]] [[treatment]] [[for]] [[patients]]. | * [[After]] [[the]] [[initial]] [[diagnosis]] [[of]] [[Barrett's esophagus]] [[is]] [[rendered]], [[affected]] [[persons]] [[undergo]] [[annual]] [[surveillance]] [[to]] [[detect]] [[changes]] [[that]] [[indicate]] [[higher]] [[risk]] [[to]] [[progression]] [[to]] [[cancer]]: [[development]] [[of]] [[dysplasia]]. [[There]] [[is]] [[considerable]] [[variability]] [[in]] [[assessment]] [[for]] [[dysplasia]] [[among]] [[pathologists]]. [[Recently]], [[gastroenterology]] and [[GI]] [[pathology]] [[societies]] [[have]] [[recommended]] [[that]] [[any]] [[diagnosis]] [[of]] [[high]] [[grade]] [[dysplasia]] [[in]] [[Barrett's]] [[be]] [[confirmed]] [[by]] [[at]] [[least]] [[two]] [[fellowship]] [[trained]] [[GI]] [[pathologists]] [[prior]] [[to]] [[definitive]] [[treatment]] [[for]] [[patients]]. | ||
Revision as of 14:45, 22 November 2017
|
Barrett's Esophagus Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Barrett's esophagus pathophysiology On the Web |
|
American Roentgen Ray Society Images of Barrett's esophagus pathophysiology |
|
Risk calculators and risk factors for Barrett's esophagus pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Amresh Kumar MD [2]
Pathophysiology
- Barrett's esophagus is marked by the presence of columnar epithelium in the lower esophagus, replacing the normal squamous cell epithelium; an example of metaplasia. The columnar epithelium is better able to withstand the erosive action of the gastric secretions; however, this metaplasia confers an increased cancer risk of the adenocarcinoma type.[1]
- The metaplastic columnar cells may be of two types: gastric (similar to those in the stomach, which is NOT technically Barrett's esophagus) or colonic (similar to cells in the intestine). A biopsy of the affected area will often contain a mixture of the two. Colonic-type metaplasia is the type of metaplasia associated with increased risk of malignancy in genetically susceptible people.
- The metaplasia of Barrett's esophagus is visible grossly through a gastroscope, but biopsy specimens must be examined under a microscope to determine whether cells are gastric or colonic in nature. Colonic metaplasia is usually identified by finding goblet cells in the epithelium and is necessary for the final diagnosis of Barrett's.
- There are many histological mimics of Barrett's esophagus (i.e. goblet cells occurring in the transitional epithelium of normal esophageal submucosal gland ducts, "pseudogoblet cells" in which abundant foveolar (gastric) type mucin simulates the acid mucin true goblet cells). Assessment of relationship to submucosal glands and transitional-type epithelium with examination of multiple levels through the tissue may allow the pathologist to reliably distinguish between goblet cells of submucosal gland ducts and true Barrett's esophagus (specialized columnar metaplasia). Use of the histochemical stain Alcian blue (with pH=2.5) is also frequently used to distinguish true intestinal-type mucin from their histological mimics. Recently, immunohistochemical analysis with antibodies to CDX-2 (specific for mid and hind-gut intestinal derivation) has also been utilized to identify true intestinal-type metaplastic cells.
- In the United States, it is estimated that 8 - 12% of patients who are diagnosed with Barrett's esophagus have been misdiagnosed. This significant diagnostic error may result in higher rates of medical and life insurance rates for those misdiagnosed; as well as enrollment of patients in unnecessary surveillance programs (i.e. annual endoscopic evaluation and biopsy to monitor for the development of Barrett's esophagus). Second (consulting) opinions on pathologic materials are easily available as slides and tissue blocks are retained [[for] 10 and 20 years, respectively. To request a consultation opinion, patients may contact their gastroenterologist for referral to a GI pathology specialty center.
- After the initial diagnosis of Barrett's esophagus is rendered, affected persons undergo annual surveillance to detect changes that indicate higher risk to progression to cancer: development of dysplasia. There is considerable variability in assessment for dysplasia among pathologists. Recently, gastroenterology and GI pathology societies have recommended that any diagnosis of high grade dysplasia in Barrett's be confirmed by at least two fellowship trained GI pathologists prior to definitive treatment for patients.
- Recent evidence has pointed to a similar condition developing in the distal gut epithelium. Barrett's Anus is a metaplastic change in [[the] distal rectum whose cellularity is similar to that of the gastric mucosa. While the condition is stable for many years, there has been recent evidence to show that it is the predisposing lesion to both anal teratoma and squamous cell carcinoma of the anus. Frequent bouts of steatorrhea are commonly cited as the most likely cause of Barrett's Anus, but much more research needs to be done in order to rule out causes such as HPV 8,13.
- It appears that chronic GE reflux is causes the injury – repair cycle that stimulates squamous metaplasia. The columnar cells are more resistant to acid injury than the squamous cells.
- Although one would think that BE develops over years, with slow replacement of squamous cells by columnar cells, it appears that this is not the case. BE tends to develop all at once with little or no progression. The reason for this is unknown.
- Paull et.al. described three types of columnar epithelium that can be seen in BE:
- Gastric junctional-type epithelium which has a pitted (foveolar) surface and mucus-secreting cells.
- Gastric fundus-type epithelium that also has a pitted surface lined [[by] mucus-secreting cells, in addition to having a deeper glandular layer that contains chief and parietal cells.
- Specialized intestinal (columnar) metaplasia that has a villiform surface with mucus secreting columnar cells and goblet cells.
Microscopic Pathology
- On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].